https://rijournals.com/research-in-medical-sciences/

RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(3):70-76, 2025

ONLINE ISSN: 1115- 6198

Print ISSN: 1597-3107

https://doi.org/10.59298/RIJRMS/2025/437076

Synergistic Potential of Herbal Polytherapy in Benign Prostatic Hyperplasia: An Integrative Phytomedicine Perspective

Okello Abura L.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Benign prostatic hyperplasia (BPH) is a prevalent age-related urological disorder associated with progressive prostate gland enlargement and lower urinary tract symptoms (LUTS). While conventional therapies such as alpha-blockers and 5-alpha reductase inhibitors offer symptom relief, they are often accompanied by adverse effects and limited long-term efficacy. Increasingly, interest is growing in phytotherapeutic approaches that harness the therapeutic synergy of multiple herbal compounds. Herbal polytherapy, the use of combinations of medicinal plants, is rooted in traditional medicine systems and increasingly supported by experimental evidence. This review explores the integrative phytomedicine perspective of herbal polytherapy in BPH management, emphasizing the mechanistic rationale for combining herbs, their multi-targeted effects on inflammation, oxidative stress, hormonal modulation, apoptosis, and smooth muscle relaxation. Notable herbal combinations, including Serenoa repens, Pygeum africanum, Urtica dioica, Curcuma longa, and Camellia sinensis, are examined for their synergistic interactions and evidence of clinical efficacy. The pharmacokinetic and safety challenges of polyherbal formulations are discussed alongside emerging nanotechnological strategies to enhance bioavailability. The review advocates for standardized, evidence-based integration of herbal polytherapy into BPH treatment regimens and calls for rigorously designed clinical trials to establish efficacy, dosage guidelines, and safety in diverse populations.

Keywords: Benign prostatic hyperplasia, Herbal polytherapy, Phytomedicine, Synergistic effects, Prostatic inflammation

INTRODUCTION

Benign prostatic hyperplasia (BPH) is a highly prevalent, non-malignant enlargement of the prostate gland affecting a significant proportion of men as they age [1]. Epidemiological studies reveal that up to 50 percent of men in their 50s and as many as 90 percent of men aged 80 and above exhibit histological evidence of BPH [1]. The clinical manifestations of BPH are typically lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, nocturia, weak urinary stream, hesitancy, and incomplete bladder emptying [2]. These symptoms contribute substantially to impaired quality of life, increased healthcare utilization, and economic burden on aging populations [2]. Conventional pharmacological therapies for BPH include alpha-adrenergic blockers, which reduce smooth muscle tone in the bladder neck and prostate, and 5-alpha reductase inhibitors, which block the conversion of testosterone to dihydrotestosterone (DHT), the principal hormonal driver of prostate growth [1]. While these treatments can provide symptomatic relief and slow disease progression, they are not curative and are often associated with adverse effects such as orthostatic hypotension, erectile dysfunction, ejaculatory disorders, and diminished libido [3]. These limitations, alongside a growing preference for natural and holistic healthcare approaches, have prompted renewed interest in phytotherapeutics.

Herbal medicine has long been used across various traditional systems, including Ayurveda, Traditional Chinese Medicine, and African ethnomedicine, to manage urological disorders [4]. Herbal polytherapy, which involves the combination of multiple plant-based extracts or compounds, represents a central philosophy in these traditions. The

rationale is that using a synergistic mixture of herbs allows for a more comprehensive targeting of disease mechanisms, while potentially minimizing toxicity and enhancing overall efficacy [5]. In the context of BPH, this approach offers the advantage of simultaneously addressing the diverse pathological mechanisms involved, including hormonal dysregulation, inflammation, oxidative stress, stromal and epithelial proliferation, and impaired apoptosis [1]. Recent scientific advancements have begun to validate the efficacy of such polyherbal formulations through preclinical experiments and clinical trials. However, there remains a need for more in-depth exploration of the synergistic mechanisms underlying these combinations, as well as the pharmacokinetic and safety profiles of multi-herb preparations. This review therefore provides an integrative perspective on the use of herbal polytherapy in the management of BPH, emphasizing mechanistic insights, evidence of synergy, and clinical translation potential.

Pathophysiology of BPH and Therapeutic Targets

The pathogenesis of BPH is multifactorial, involving a complex interplay of hormonal, inflammatory, metabolic, and age-related factors. Central to its development is the role of androgens, particularly the potent metabolite dihydrotestosterone (DHT), which is synthesized from testosterone by the enzyme 5-alpha reductase [6]. DHT binds to androgen receptors in prostate epithelial and stromal cells, promoting the transcription of genes involved in cellular proliferation and survival [7]. As men age, increased activity of 5-alpha reductase, coupled with declining circulating testosterone levels, leads to a higher DHT-to-testosterone ratio within the prostate, driving hyperplasia [8].

In addition to androgenic stimulation, chronic low-grade inflammation plays a pivotal role in BPH pathophysiology [9]. Prostatic tissue from BPH patients often shows infiltration by immune cells such as macrophages and T lymphocytes, which release pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) [10]. These inflammatory mediators activate downstream signaling cascades such as nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription (STAT), which further promote cellular proliferation, angiogenesis, and tissue remodeling [11].

Oxidative stress is another critical contributor to BPH progression. The prostate is particularly susceptible to oxidative damage due to its high content of polyunsaturated fatty acids and relatively low antioxidant defense capacity [12]. Excess reactive oxygen species (ROS) generated during aging and inflammation cause lipid peroxidation, DNA damage, and mitochondrial dysfunction, exacerbating the hyperplastic process and impairing apoptosis [13]. Moreover, oxidative stress enhances the expression of inflammatory genes and androgen receptor sensitivity, creating a self-sustaining cycle [14]. Additional factors implicated in BPH include dysregulated growth factor signaling (e.g., insulin-like growth factor-1, epidermal growth factor), autonomic nervous system overactivity, and altered extracellular matrix composition [15]. Importantly, BPH is not a uniform disease but varies among individuals in terms of symptom severity, gland size, and response to treatment [1]. Effective management strategies for BPH should therefore target multiple aspects of its pathophysiology. These include inhibition of 5-alpha reductase, suppression of pro-inflammatory signaling, attenuation of oxidative stress, induction of apoptotic pathways, modulation of smooth muscle tone, and regulation of stromal remodeling [11]. Herbal polytherapy is uniquely suited to this approach because of its capacity to harness diverse phytochemicals that collectively exert anti-inflammatory, antioxidant, anti-androgenic, and anti-proliferative effects.

Mechanisms and Rationale of Herbal Polytherapy

Herbal polytherapy, defined as the strategic use of multiple medicinal herbs in combination, is predicated on the belief that complex diseases require multifaceted interventions [16]. This principle aligns with contemporary understandings of systems biology and polypharmacology, which acknowledge that targeting multiple nodes within a disease network can enhance therapeutic efficacy and resilience against resistance mechanisms. In BPH, herbal polytherapy provides several mechanistic advantages. First, the diverse phytoconstituents present in different herbs can act on complementary molecular pathways. For example, while one herb may inhibit 5-alpha reductase activity and reduce DHT levels, another may suppress inflammatory cytokines, and yet another may scavenge ROS and enhance antioxidant enzyme expression [17]. The simultaneous modulation of these pathways can lead to additive or synergistic effects that exceed the sum of individual actions. Second, certain phytochemicals can enhance the pharmacokinetics of others by improving absorption, inhibiting metabolic degradation, or facilitating tissue-specific distribution [18]. This form of pharmacokinetic synergy can increase bioavailability and prolong the therapeutic window of the active compounds. For instance, piperine from black pepper is known to increase the systemic availability of curcumin by inhibiting its glucuronidation [19].

Third, herbal polytherapy can reduce the required dosage of each individual component, thereby minimizing the risk of toxicity or side effects. This dose-sparing effect is particularly valuable in elderly patients with comorbidities who may be taking multiple medications [20]. Additionally, combining herbs with different modes of action may reduce the likelihood of treatment resistance or tachyphylaxis that can occur with monotherapy [21].

From a practical perspective, herbal polytherapy also reflects real-world usage patterns. Many patients with BPH already consume herbal supplements, often in combination, based on cultural practices or personal preference [22]. Standardizing and scientifically validating these combinations is therefore essential to ensure safety, efficacy, and reproducibility.

Ultimately, the rationale for herbal polytherapy in BPH lies in its capacity to deliver a systems-based, multi-targeted approach that is congruent with the complex and chronic nature of the disease. The integration of such phytotherapeutic strategies into mainstream clinical practice holds the potential to expand therapeutic options, improve patient outcomes, and reduce reliance on conventional medications with undesirable side effects.

Key Herbal Combinations Used in Polytherapy for BPH

Numerous herbs have been studied for their efficacy in benign prostatic hyperplasia (BPH), but recent investigations increasingly highlight the enhanced outcomes derived from combining select herbal agents. The foundation of such combinations lies in their complementary mechanisms that target the multifaceted pathophysiology of BPH. These herbs are often selected based on evidence of anti-androgenic activity, antioxidant capacity, anti-inflammatory effects, and smooth muscle relaxant properties.

Serenoa repens (saw palmetto) is perhaps the most widely studied botanical agent for BPH [23]. It exerts multiple effects including inhibition of 5-alpha reductase, antagonism of DHT binding to androgen receptors, and reduction of pro-inflammatory prostaglandins [24]. When combined with Urtica dioica (stinging nettle), the effectiveness of saw palmetto is enhanced [25]. Urtica dioica inhibits sex hormone-binding globulin (SHBG) and exhibits anti-proliferative and anti-edematous effects, thereby reducing prostatic inflammation and cellular hyperplasia [26].

Pygeum africanum (African plum bark) is another effective component in polyherbal formulations. It contains phytosterols and ferulic acid esters that exhibit anti-inflammatory and anti-androgenic activities while also improving bladder contractility and reducing residual urine volume [27]. Its combination with saw palmetto has shown superior clinical outcomes compared to either agent alone, particularly in reducing nocturia and improving peak urinary flow.

Curcuma longa (turmeric), through its active constituent curcumin, adds value to herbal polytherapy by modulating oxidative stress and downregulating nuclear factor-kappa B (NF-κB) signaling, which is involved in chronic prostatic inflammation [28]. Curcumin also promotes apoptotic pathways in hyperplastic cells and enhances tissue remodeling [29].

Camellia sinensis (green tea), especially its catechin epigallocatechin gallate (EGCG), contributes to anti-proliferative and antioxidant defenses [30]. EGCG also reduces DHT synthesis and suppresses pro-inflammatory cytokine production [31].

Herbal formulations combining these agents—such as saw palmetto, nettle root, pygeum, and green tea extract—have been commercialized and tested in clinical trials [17]. These combinations are shown to exert additive or synergistic effects on IPSS scores, prostate volume, and urinary flow metrics. Importantly, the use of standardized extracts ensures reproducibility and potency, making these combinations viable adjuncts or alternatives to conventional BPH therapy.

Evidence from Preclinical and Clinical Studies

Preclinical studies have consistently demonstrated the efficacy of herbal polytherapy in animal models of BPH. Rodents treated with polyherbal combinations, particularly those containing saw palmetto and pygeum, exhibit significant reductions in prostate weight, histological improvement, and decreased expression of pro-inflammatory cytokines [24]. Studies using testosterone or estrogen-induced BPH models further show normalization of androgen receptor expression and restoration of antioxidant enzyme levels [24]. In clinical trials, multi-herb supplements have shown efficacy comparable to pharmacological agents such as finasteride and tamsulosin. One randomized controlled trial involving a combination of saw palmetto and nettle root demonstrated a 35 percent improvement in IPSS after 24 weeks, with significant increases in maximum urinary flow rate and decreased post-void residual urine [32]. Importantly, adverse effects were minimal to mild gastrointestinal symptoms. Another study evaluating a triple combination of saw palmetto, pygeum, and pumpkin seed oil reported sustained symptomatic improvement and better tolerability than synthetic drugs [33]. Moreover, clinical trials assessing green tea catechins and curcumin as adjunct therapies revealed enhanced outcomes in patients who were previously non-responsive to monotherapy [34]. Despite these promising results, methodological limitations remain. Many studies lack sufficient sample sizes, long-term follow-up, or standardized formulations. Additionally, differences in extract preparation, dosage, and study design hinder comparability. Nevertheless, the consistency of findings across diverse populations underscores the therapeutic potential of herbal polytherapy in BPH management.

Pharmacokinetics and Bioavailability Challenges

One of the major challenges in the clinical application of herbal polytherapy lies in the pharmacokinetic limitations of phytochemicals. Many active constituents, such as curcumin, quercetin, and EGCG, exhibit poor oral

bioavailability due to low aqueous solubility, extensive first-pass metabolism, and rapid systemic clearance [35, 36, 37, 38, 39, 40]. These limitations can significantly impact the clinical efficacy of herbal combinations unless addressed through formulation improvements. For example, the co-administration of piperine from black pepper with curcumin has been shown to enhance bioavailability by over 2000 percent by inhibiting glucuronidation [36]. Lipid-based carriers, such as liposomes and solid lipid nanoparticles, have also been used to improve the absorption and systemic delivery of lipophilic compounds [41, 42, 43, 44, 45].

Another promising approach is the use of phytosomes, which are complexes of plant extracts with phospholipids. Phytosomes improve intestinal permeability and stability, allowing for better systemic distribution and tissue penetration [46, 47, 48, 49]. This delivery method has shown success in increasing the bioefficacy of curcumin and green tea catechins in urological applications [50, 51, 52, 53]. Importantly, combining herbs in a polyherbal formulation can create both pharmacokinetic enhancement and competition. While one component may improve the absorption of another, overlapping metabolic pathways could lead to competitive inhibition or altered clearance. Therefore, thorough evaluation of herb-herb interactions, metabolism, and plasma half-life is essential in the formulation of effective and safe polyherbal preparations [54, 55, 56, 57, 58].

Safety Considerations and Standardization Issues

Herbal polytherapy is generally perceived as safe, especially when using agents that are part of traditional diets or ethnomedicinal practices. However, safety cannot be presumed without rigorous evaluation. While most polyherbal BPH formulations have favorable side effect profiles, risks such as gastrointestinal discomfort, allergic reactions, and hepatotoxicity at high doses have been reported in some cases [50, 51, 52, 53, 54]. One major concern is the lack of standardization across commercial formulations. Variations in plant source, harvesting methods, extraction procedures, and final product composition can lead to inconsistencies in therapeutic outcomes and safety profiles [55, 56, 57, 58]. Furthermore, contamination with heavy metals, pesticides, or adulterants poses additional health risks. To address these issues, good manufacturing practices (GMP), validated analytical techniques such as HPLC and mass spectrometry, and strict regulatory oversight must be implemented. Quantification of active ingredients and toxicological assessment of complete formulations should be mandatory before clinical application. Finally, patient education and clinician training are paramount. Herbal polytherapy should be used under professional guidance, especially when patients are on multiple medications that may interact with phytochemicals [39]. Continued pharmacovigilance and post-market surveillance are needed to monitor safety and adverse events associated with long-term use.

CONCLUSION

Herbal polytherapy offers a promising, multi-targeted approach to the management of BPH, addressing key pathophysiological drivers such as hormonal imbalance, oxidative stress, and inflammation. Through synergistic interactions, polyherbal combinations can provide therapeutic benefits equivalent to or surpassing conventional monotherapies, with fewer side effects. Future research should focus on standardization, mechanistic validation, and clinical implementation of these formulations within an integrative medical framework.

REFERENCES

1. Ibiam UA, Uti DE, Ejeogo CC, Orji OU, Aja PM, Ezeaani NN, et al. In Vivo and in Silico Assessment of Ameliorative Effects of Xylopia aethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia. *Pharmaceut Fronts*. 2023;5: e64–e76. DOI:10.1055/s-0043-1768477
2. Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postgraduate Medicine. 2015;127(3):301–7. doi:10.1080/00325481.2015.1018799
3. Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Translational Andrology and Urology. 2017;6(2):295–304. doi:10.21037/tau.2017.03.57
4. Edyedu I, Ugwu OP, Ugwu CN, Alum EU, Eze VHU, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE, Aja PM. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. Medicine (Baltimore). 2025 Feb 14;104(7):e41381. doi: 10.1097/MD.0000000000041381. PMID: 39960970; PMCID: PMC11835077.
5. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393
6. Uhuo EN, Egba SI, Obike CA, Anyiam PN, Alaebo PO, Okeke PM, et al. Combined extracts of Syzygium aromaticum (Clove) and Xylopia aethiopica (Negro pepper) seeds inhibit testosterone propionate-induced benign prostatic hyperplasia in Wistar rats. All Life [Internet]. 2024 Dec 5;17(1). Available from:https://www.tandfonline.com/doi/epdf/10.1080/26895293.2024.2435277

7. Ibiam UA, Uti DE, Ejeogo CC, Orji OU, Aja PM, Ezeani NN., et al. Xylopia aethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences. 2024, 01: 1-148. https://doi.org/10.1055/s-0043-1777836.
8. Kinter KJ, Amraei R, Anekar AA. Biochemistry, dihydrotestosterone. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557634/
9. Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation. 2020;2020:1–7. doi:10.1155/2020/7958316
10. Ugwu, CE., Sure, SM., Dike, CC., Okpoga, NA and Egba, SI. Phytochemical and *in vitro* antioxidant activities of methanol leave extract of *Alternanthera basiliana*. Journal of Pharmacy Research, 2018; 12(6): 835-839
11. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204–18. doi:10.18632/oncotarget.23208
12. Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. Journal of Experimental & Clinical Cancer Research. 2016;35(1). doi:10.1186/s13046-016-0418-8
13. Afzal S, Manap ASA, Attiq A, Albokhadaim I, Kandeel M, Alhojaily SM. From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1269581
14. Song Y, Hou Z, Zhu L, Chen Y, Li J. Oxidative stress as a catalyst in prostate cancer progression: unraveling molecular mechanisms and exploring therapeutic interventions. Discover Oncology. 2025;16(1). doi:10.1007/s12672-025-02245-4
15. Uroko Robert Ikechukwu, Fatima Amin Adamude, Egba Simeon Ikechukwu, Chinedu Paulinus Nwuke, Chidinma Lilian Asadu and Peter Anyaorah. Effect of combined ethanol extract of Funtumia Africana and Abutilon mauritanium leaves on prostate biomarkers and serum mineral levels in prostatic hyperplasia induced in rats. J. Renal Endocrinol 2021; 7:e06
16. Kiyohara H, Matsumoto T, Yamada H. Combination effects of herbs in a multi-herbal formula: expression of Juzen-taiho-to's immuno-modulatory activity on the intestinal immune system. Evidence-Based Complementary and Alternative Medicine. 2004;1(1):83–91. doi:10.1093/ecam/neh004
17. IR Uroko, F A Adamude, S I Egba, C N Chukwu, C L Asadu, E C Okwara. Effects of combined ethanol extract of *Funtumia africana* and *Abutilon mauritianum* leaves (FAAM) on liver function indices of benign prostatic hyperplasia (BPH) induced rats, Herba Polonica,2020; 66 (3): 24-35
18. Hu Y, Lin Q, Zhao H, Li X, Sang S, McClements DJ, et al. Bioaccessibility and bioavailability of phytochemicals: influencing factors, improvements, and evaluations. Food Hydrocolloids. 2022;135:108165. doi:10.1016/j.foodhyd.2022.108165
19. Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology. 2012;75(2):450–62. doi:10.1111/j.1365-2125.2012.04364.x
20. Ochulor Okechukwu C., Njoku Obioma U., Uroko Robert I and Egba Simeon I. Nutritional composition of *Jatropha tanjorensis* leaves and effects of its aqueous extract on carbon tetrachloride induced oxidative stress in male Wistar albino rats. Biomedical Research 2018; 29(19): 3569-3576
21. Che CT, Wang Z, Chow M, Lam C. Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules. 2013;18(5):5125–41. doi:10.3390/molecules18055125
22. Zeng H, Wang Z, Zhu W, Li X, Liu B, Chen C, et al. Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2024;15. doi:10.3390/fphar.2024.1358340
23. Franco JV, Trivisonno L, Sgarbossa NJ, Alvez GA, Fieiras C, Liquitay CME, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Library. 2023;2023(6). doi:10.1002/14651858.CD001423.PUB4
24. Robert I. Uroko., Charles N. Chukwu., Simeon I. Egba., Fatima A. Adamude andJoy C. Ajuzie Combined ethanol extract of *Funtumia africana* and *Abutilon mauritianium* leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats. Acta Sci. Pol. Technol. Aliment. 2020; 19(4): 395-404

25. Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tract symptoms. Planta Medica. 2001;67(6):489–500. doi:10.1055/s-2001-16496
26. Sleiman MA, Younes M, Hajj R, Salameh T, Rached SA, Younes RA, et al. Urtica dioica: anticancer properties and other systemic health benefits from in vitro to clinical trials. International Journal of Molecular Sciences. 2024;25(13):7501. doi:10.3390/ijms25137501
27. Villar A, Silva-Fuentes F, Mulà A, Zangara A. Anti-inflammatory potential of Pygeum africanum bark extract: an in vitro study of cytokine release by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. International Journal of Molecular Sciences. 2024;25(15):8298. doi:10.3390/ijms25158298
28. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, et al. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Frontiers in Pharmacology. 2020;11. doi:10.3389/fphar.2020.01021
29. Wang X, Tian Y, Lin H, Cao X, Zhang Z. Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling. Open Life Sciences. 2023;18(1). doi:10.1515/biol-2022-0618
30. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemical Pharmacology. 2011;82(12):1807–21. doi:10.1016/j.bcp.2011.07.093
31. Im M, Kim SY, Sohn KC, Choi DK, Lee Y, Seo YJ, et al. Epigallocatechin-3-gallate suppresses IGF-I-induced lipogenesis and cytokine expression in SZ95 sebocytes. Journal of Investigative Dermatology. 2012;132(12):2700–8. doi:10.1038/jid.2012.202
32. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58(6):960–3. doi:10.1016/S0090-4295(01)01442-X
33. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice. 2009;3(4):323. doi:10.4162/nrp.2009.3.4.323
34. Kunnumakkara AB, Hegde M, Parama D, Girisa S, Kumar A, Daimary UD, et al. Role of turmeric and curcumin in prevention and treatment of chronic diseases: lessons learned from clinical trials. ACS Pharmacology & Translational Science. 2023;6(4):447–518. doi:10.1021/acsptsci.2c00012
35. Alum EU, Udechukwu CD, Obasi DC. RNA signaling in medicinal plants: An overlooked mechanism for phytochemical regulation. Biochemistry and Biophysics Reports, 42(2025):102032. doi: 10.1016/j.bbrep.2025.102032. PMID: 40342531; PMCID: PMC12059694.
36. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353–6. doi:10.1055/s-2006-957450
37. Uti DE, Alum EU, Atangwho IJ, Ugwu OPC, Egbung GE, Aja PM. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. *J Nanobiotechnol* **23**, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
38. Nsairat H, Khater D, Odeh F, Jaber AM, Sulaibi MAMA, Alshaer W, et al. Phytosomes: a modernistic approach to the delivery of herbal drugs. In: Elsevier eBooks. 2023. p. 301–55. doi:10.1016/B978-0-323-91668-4.00029-0
39. Hussain S. Patient counseling about herbal-drug interactions. African Journal of Traditional, Complementary and Alternative Medicines. 2011;8(5 Suppl). doi:10.4314/ajtcam.v8i5s.8
40. Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). 2014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463967/
41. Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, Obasi OD, Nwali BU. Evaluation of the phytochemical and nutritional profiles of Cnidoscolus aconitifolius leaf collected in Abakaliki South East Nigeria. World J Med Sci. 2016;13(3):213-217.
42. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu Okechukwu PC. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in *Plasmodium berghei*-infected mice. Glob Veterinaria. 2016;16(1):57-66.
43. Alum EU, Uti DE, Ugwu Okechukwu PC, Alum BN. Toward a cure–Advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: A review. Med. 2024;103(27):e38768.

44. Obeagu EI, Bot YS, Obeagu GU, Alum EU, Ugwu Okechukwu PC. Anaemia and risk factors in lactating mothers: A concern in Africa. Int J Innov Appl Res. 2024;11(2):15-17.
45. Alum EU, Ibiam UA, Ugwuja EI, Aja PM, Igwenyi IO, Offor CE, Orji UO, Ezeani NN, Ugwu OP, Aloke C, Egwu CO. Antioxidant effect of Buchholzia coriacea ethanol leaf extract and fractions on Freund's adjuvant-induced arthritis in albino rats: A comparative study. 2022;59(1):31-45.
46. Offor CE, Ugwu Okechukwu PC, Alum EU. Determination of ascorbic acid contents of fruits and vegetables. Int J Pharm Med Sci. 2015;5:1-3.
47. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. IAA J Biol Sci. 2024;10(1):109-117.
48. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. IAA J Biol Sci. 2024;10(1):109-117.
49. Enechi YS, Ugwu OC, Ugwu Okechukwu PC, Omeh K. Evaluation of the antinutrient levels of *Ceiba pentandra* leaves. IJRRPAS. 2013;3(3):394-400.
50. Ugwu Okechukwu PC, Nwodo OFC, Joshua EP, Odo CE, Ossai EC. Effect of ethanol leaf extract of *Moringa oleifera* on lipid profile of malaria-infected mice. Res J Pharm Biol Chem Sci. 2014;4(1):1324-1332.
51. Ugwu OPC, Alum EU, Uhama KC. Dual burden of diabetes mellitus and malaria: Exploring the role of phytochemicals and vitamins in disease management. Res Inven J Res Med Sci. 2024;3(2):38-49.
52. Alum EU, Ugwu Okechukwu PC, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of *Datura stramonium* against methotrexate-induced hematological impairments. Cogent Food Agric. 2013;9(1):2258774.
53. Offor CE, Nwankwegu FC, Joshua EP, Ugwu Okechukwu PC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform-methanol extract of the leaves of *Persea americana*. Iran J Pharm Res. 2014;13(2):651-658. PMID: 25237361; PMCID: PMC4157041.
54. Afiukwa CA, Oko AO, Afiukwa JN, Ugwu Okechukwu PC, Ali FU, Ossai EC. Proximate and mineral element compositions of five edible wild grown mushroom species in Abakaliki, southeast Nigeria. Res J Pharm Biol Chem Sci. 2013;4:1056-1064.
55. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. Med. 2024;103(28):e38834.
56. Obeagu EI, Ugwu OPC, Alum EU. Poor glycaemic control among diabetic patients; A review on associated factors. Newport Int J Res Med Sci (NIJRMS). 2023;3(1):30-33.
57. Nwaka AC, Ikechi-Agba MC, Okechukwu PU, Igwenyi IO, Agbafor KN, Orji OU, Ezugwu AL. The effects of ethanol extracts of *Jatropha curcas* on some hematological parameters of chloroform intoxicated rats. Am-Eur J Sci Res. 2015;10(1):45-49.
58. Ezeani NN, Ibiam UA, Orji OU, Igwenyi IO, Aloke C, Alum E, Aja PM, Ugwu OP. Effects of aqueous and ethanol root extracts of *Olax subscopioidea* on inflammatory parameters in complete Freund's adjuvant-collagen type II induced arthritic albino rats. Pharmacogn J. 2019;11(1)

CITE AS: Okello Abura L. (2025). Synergistic Potential of Herbal Polytherapy in Benign Prostatic Hyperplasia: An Integrative Phytomedicine Perspective. RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(3):70-76. https://doi.org/10.59298/RIJRMS/2025/437076